Compounded Oral Semaglutide vs Rybelsus and the Wegovy Pill

Novo Nordisk took the same SNAC technology to a much higher strength and ran it through the OASIS trials. In OASIS 4 — 307 adults with overweight or obesity, no diabetes, 64 weeks — participants who stayed on the tablet lost 16.6% of their body weight against 2.7% on placebo; counting everyone regardless of adherence, 13.6% against 2.2%. Around a third lost a fifth of their body weight or more. Serious adverse events were actually less frequent on the tablet than on placebo.

The FDA approved it on December 22 2025 for chronic weight management and, carrying over from the injectable, for reducing major cardiovascular events. It is the first oral GLP-1 with a weight-loss indication and — because it is the same molecule as the injection — the first with cardiovascular outcomes data behind it.

The ritual is the same as Rybelsus. That is the trade: a needle-free semaglutide with injection-class results, in exchange for a strict morning routine every day.

A compounded oral semaglutide is semaglutide put into a capsule by a pharmacy, usually with an absorption enhancer of the pharmacy's choosing, at a strength of the prescriber's choosing. It has been through no trial. Its absorption has not been measured in the way SNAC's has. Two capsules from two pharmacies may behave quite differently, and neither has been compared to the Wegovy pill.

That does not make it worthless. It makes it a product whose evidence is borrowed — from the injectable trials for the molecule and from the SNAC trials for the idea of oral delivery — rather than earned. The honest way to describe it is: the same drug, a plausible route, an unknown fraction absorbed.

For most of the compounded era the justification was that no approved oral weight-loss semaglutide existed. As of December 2025 that justification is gone, and the regulatory pressure on compounded GLP-1s described on the injectable comparison page applies with at least as much force here.

If a needle is the barrier and the morning routine is not, the Wegovy pill is the product with the evidence, and where coverage allows it is the one we would reach for.

If the routine is the barrier — shift work, travel, a morning that does not permit a quiet fasted half-hour — then an oral route of any kind may be the wrong answer and the weekly injection the right one. The compounded capsule has the same absorption constraints; it does not escape them.

If neither approved oral product is accessible to you, a compounded capsule may be considered, with the understanding that its results will be less predictable and its regulatory footing narrower. That is a conversation we will have plainly rather than one we will sell.

And for the patient for whom daily anything is a struggle, orforglipron — approved in April 2026, no food or water restrictions — is the first oral GLP-1 that removes the ritual entirely. It is a different molecule with a smaller effect, and it belongs in the comparison.